key: cord-301478-j4b2534p
authors: Gisondi, Paolo; Zaza, Gianluigi; Del Giglio, Micol; Rossi, Mattia; Iacono, Valentina; Girolomoni, Giampiero
title: Risk of hospitalization and death from COVID-19 infection in patients with chronic plaque psoriasis receiving a biological treatment and renal transplanted recipients in maintenance immunosuppressive treatment
date: 2020-04-21
journal: J Am Acad Dermatol
DOI: 10.1016/j.jaad.2020.04.085
sha: 
doc_id: 301478
cord_uid: j4b2534p

nan

Manuscript words: 493 13 We performed a retrospective observational study in order to determine whether Hospital and compared to the Verona population (n=257,353) ( Table 1 ). The overall study 60 population is resident in Verona, so that its reference Hospital is the same. Data of Verona 61 residents were derived from national public database. 4 Data are expressed as means ± 62 SD or percentages. Statistical analyses for comparison between patients and general 63 population included the unpaired-t test, and theχ2-test. 64

As of April 10, 2020, the total number of COVID 19-positive patients (including 65 those that did not require hospitalization or die) in Verona was 3,199 (1.2% of population). -Legend: * asymptomatic individuals were not tested so the true number of COVID-19 positive patients is unknown; CNI: calcineurin inhibitors; mTORi mammalian target of rapamaycin; PsA: psoriatic arthritis; PsO: psoriasis Data of psoriasis and transplant patients are derived from electronic medical record of the Hospital. Data of general population are derived from https://www.azero.veneto.it/-/emergenza-coronavirus and https://www.epicentro.iss.it and http://demo.istat.it accessed on 10th April 2020.

Guidance on the use of biologic agents during COVID-19 outbreak

American Academy of 93 Dermatology

Should patients stop their biologic treatment during the 95 COVID-19 pandemic

Should biologics for psoriasis be 97 interrupted in the era of COVID-19?